Paris

• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting
  2023-505766-28-00 10 2022-10-10 Hereditary angioedema
• First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide … Recruiting
  2023-503795-24-00 7 2022-09-16 Avanced Non-Small Cell Lung Cancer
• A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t … Recruiting
  2022-500461-28-06 5 2022-09-15 High-Risk Metastatic Hormone-Sensitive Prostate Cancer
• Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Subcutaneously in Children With Generalized Myasthenia Gravis (AD … Recruiting
  2023-507379-23-00 10 2022-08-18 Generalized Myasthenia Gravis
• The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR … Recruiting
  2024-512119-34-00 4 2022-06-20 MSI-H/dMMR metastatic colorectal cancer
• A Phase 1/2/3 Study of UX701 Gene Therapy in Adults with Wilson Disease”. Recruiting
  2022-502873-40-00 7 2022-06-13 Wilson disease
• BIVV020 (SAR445088) in prevention and treatment of antibody-mediated rejection (AMR) Recruiting
  2023-509936-25-00 4 2022-06-09 Transplant Rejection
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral oza … Recruiting
  2023-509248-86-00 10 2022-03-11 Moderately to Severely Active Ulcerative Colitis
• OPEN LABEL, MAINTENANCE STUDY OF ORAL TOFACITINIB IN CHILDREN WITH MODERATE TO SEVERE ULCERATIVE COLITIS Recruiting
  2023-509694-22-00 5 2022-01-26 Ulcerative Colitis (UC)
• Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of … Recruiting
  2024-512761-13-00 5 2022-01-24 Remyelination in Multiple Sclerosis
• A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting
  2023-505638-82-00 5 2022-01-12 Atypical Hemolytic Uremic Syndrome (aHUS)
• Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients Recruiting
  2023-509331-83-00 5 2021-07-28 complement 3 glomerulopathy
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS T … Recruiting
  2023-504084-17-00 9 2021-07-12 ALK fusion-positive extracranial solid or primary CNS tumors who have
• A Phase 1/2 Study of Bleximenib in Participants with Acute Leukemia Recruiting
  2023-506581-31-00 1 2021-06-15 Acute Leukemia
• Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the … Recruiting
  2022-501677-39-00 5 2021-05-25 Adolescent Renal Allografts
• Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies Recruiting
  2023-508883-31-00 5 2021-02-23 Solid tumors and hamatological malignancies
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l … Recruiting
  2024-511267-28-00 5 2021-02-17 B-cell malignancies
• LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting
  2023-506784-33-00 5 2021-01-19 RET fusion-Positive NSCLC
• A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl … Recruiting
  2022-501687-18-00 4 2020-10-28 Advanced malignancies and IAI diseases
• A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma. Recruiting
  2023-505261-84-00 5 2020-10-06 Primary high risk leiomyosarcoma or liposarcoma of retroperitoneal spa
• A Phase 1/2 First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia Recruiting
  2023-510509-17-00 7 2020-06-17 Relapsed and/or refractory Acute Myeloid Leukemia
• NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The … Recruiting
  2022-500966-82-00 5 2020-03-11 Resectable locally advanced squamous cell carcinoma (SCC) of the esoph

Showing 433–456 of 2,286 trials